Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 17 of 18
Next
>>
>
401 to 425 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-549	MK2206	2	72	sigmoid	sigmoid	BT549 MK-2206 0 2 72	8	1.871	Inf	0.926	0.0188	0.107	0.926	5.0	0.816	0.00627	NA	Inf	0.932	0.983	0.107	0.931	5.0	0.809	0.00694	NA
BT-549	MK2206	1	72	sigmoid	sigmoid	BT549 MK-2206 0 1 72	8	1.811	Inf	0.632	0.189	0.103	0.58	0.8	0.911	0.000695	NA	Inf	0.692	0.839	0.101	0.642	0.73	0.911	0.000717	NA
BT-549	KIN001-244	3	72	sigmoid	sigmoid	BT549 KIN001-244 0 3 72	8	1.740	Inf	0.861	0.0287	4.69	0.681	0.74	0.922	0.00047	NA	Inf	0.882	0.975	4.7	0.729	0.732	0.919	0.000531	NA
BT-549	KIN001-244	2	72	sigmoid	sigmoid	BT549 KIN001-244 0 2 72	8	1.920	Inf	0.882	0.00561	2.72	0.793	1.67	0.73	0.0197	NA	Inf	0.89	0.995	2.6	0.813	1.68	0.718	0.0225	NA
BT-549	KIN001-244	1	72	sigmoid	sigmoid	BT549 KIN001-244 0 1 72	8	1.802	Inf	0.872	0.0273	4.85	0.695	0.794	0.852	0.00324	NA	Inf	0.888	0.976	4.84	0.733	0.786	0.846	0.00362	NA
HCC1806	Alpelisib	1	72	flat	flat	HCC1806 alpelisib 0 1 72	8	2.771	Inf	0.918	0.0583	0.0	0.918	0.01	-0.337	1.0	0.94	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919
HCC1806	Alpelisib	2	72	flat	flat	HCC1806 alpelisib 0 2 72	8	2.856	Inf	0.921	0.0566	0.0	0.921	0.01	-0.336	1.0	0.941	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919
HCC1806	Alpelisib	3	72	flat	flat	HCC1806 alpelisib 0 3 72	8	3.224	Inf	0.93	0.0502	0.0	0.93	0.01	-0.335	1.0	0.948	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919
HCC1806	CAL-101	1	72	flat	flat	HCC1806 idelalisib 0 1 72	8	2.695	Inf	1.02	-0.0102	0.0	1.02	0.01	-0.593	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.587	1.0	1.02
HCC1806	CAL-101	2	72	flat	flat	HCC1806 idelalisib 0 2 72	8	2.779	Inf	1.02	-0.00985	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.588	1.0	1.02
HCC1806	CAL-101	3	72	flat	flat	HCC1806 idelalisib 0 3 72	8	3.147	Inf	1.02	-0.00869	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.587	1.0	1.02
HCC1806	Everolimus	1	72	sigmoid	sigmoid	HCC1806 everolimus 0 1 72	8	2.786	Inf	0.784	0.183	0.000282	0.748	0.187	0.86	0.00277	NA	Inf	0.727	0.765	0.00022	0.729	0.377	0.879	0.00177	NA
HCC1806	Everolimus	2	72	sigmoid	sigmoid	HCC1806 everolimus 0 2 72	8	2.871	Inf	0.79	0.178	0.000277	0.79	0.365	0.879	0.00176	NA	Inf	0.727	0.765	0.000222	0.728	0.374	0.879	0.00178	NA
HCC1806	Everolimus	3	72	sigmoid	sigmoid	HCC1806 everolimus 0 3 72	8	3.239	Inf	0.813	0.159	0.000271	0.812	0.356	0.879	0.00175	NA	Inf	0.727	0.765	0.00022	0.729	0.377	0.879	0.00177	NA
BT-549	Everolimus	2	72	flat	flat	BT549 everolimus 0 2 72	8	1.909	Inf	0.566	0.407	0.0	0.566	0.01	-0.646	1.0	0.594	Inf	0.627	0.648	0.0	0.627	0.01	-1.01	1.0	0.649
HCC1806	KIN001-244	1	72	flat	flat	HCC1806 KIN001-244 0 1 72	8	2.742	Inf	0.986	0.0236	0.0	0.986	0.01	-0.0573	1.0	0.979	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC1806	KIN001-244	2	72	flat	flat	HCC1806 KIN001-244 0 2 72	8	2.827	Inf	0.986	0.0229	0.0	0.986	0.01	-0.0574	1.0	0.98	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC1806	KIN001-244	3	72	flat	flat	HCC1806 KIN001-244 0 3 72	8	3.195	Inf	0.988	0.0203	0.0	0.988	0.01	-0.0575	1.0	0.982	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC1806	PI103	1	72	sigmoid	sigmoid	HCC1806 PI-103 0 1 72	8	2.673	Inf	0.895	0.00682	1.71	0.853	1.43	0.781	0.0106	NA	Inf	0.866	0.992	1.61	0.817	1.44	0.762	0.0134	NA
HCC1806	PI103	2	72	sigmoid	sigmoid	HCC1806 PI-103 0 2 72	8	2.758	Inf	0.898	0.00662	1.71	0.857	1.43	0.781	0.0105	NA	Inf	0.866	0.992	1.61	0.817	1.44	0.762	0.0134	NA
HCC1806	PI103	3	72	sigmoid	sigmoid	HCC1806 PI-103 0 3 72	8	3.126	Inf	0.91	0.00588	1.72	0.873	1.43	0.782	0.0103	NA	Inf	0.866	0.992	1.61	0.817	1.44	0.762	0.0134	NA
HCC1806	TGX221	1	72	flat	flat	HCC1806 TGX-221 0 1 72	8	2.679	Inf	1.0	-0.0118	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	2	72	flat	flat	HCC1806 TGX-221 0 2 72	8	2.763	Inf	1.0	-0.0114	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	3	72	flat	flat	HCC1806 TGX-221 0 3 72	8	3.132	Inf	1.0	-0.0101	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
BT-549	CAL-101	2	72	sigmoid	sigmoid	BT549 idelalisib 0 2 72	8	1.975	Inf	0.792	0.0561	4.65	0.526	0.693	0.933	0.000307	NA	43.0	0.805	0.946	43.0	0.0	0.548	0.932	0.000314	NA

|<
<<
Previous
Page 17 of 18
Next
>>
>
401 to 425 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)